

09 May 2021 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things, hear about IP waivers for coronavirus vaccines; launch records for Pfizer's COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 May 2021, including: possible intellectual property waivers for coronavirus vaccines; launch records for *Pfizer Inc.*'s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.

These and all other podcasts are available on the Informa Pharma Intelligence channel on <u>Apple Podcasts</u>, <u>Google Podcasts</u>, <u>SoundCloud</u> and <u>TuneIn</u> - and also now on <u>Spotify Podcasts</u> - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning*" - Scrip, 5 May, 2021.)

(Also see "<u>Credit Where It Is Due: Pfizer's COVID-19 Vaccine Smashes Launch Records As Expected</u>" - Scrip, 4 May, 2021.)

(Also see "Your Annual COVID-19 Vaccine Booster Could Be A Pill Or A Spray" - Scrip, 30 Apr,



2021.)

(Also see "*With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?*" - Scrip, 3 May, 2021.)

(Also see "The 2021 Worldwide Pharma And Biotech R&D Scene" - Scrip, 5 May, 2021.)

Click here to explore this interactive content online